Neuronetics

Overview

Neuronetics, Inc. (NASDAQ: STIM) is a medical device company developing and commercializing non-invasive neuromodulation therapies for the treatment of psychiatric and neurological disorders. Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics is the pioneer in Repetitive Transcranial Magnetic Stimulation (rTMS) technology for major depressive disorder (MDD)[@neuronetics2024].

The company flagship product, the NeuroStar Advanced Therapy system, is an FDA-cleared TMS device used by psychiatrists and neurologists to treat patients with major depressive disorder who have not responded to antidepressant medications[@us2008].

Funding

• IPO: 2020 (NASDAQ: STIM)
• Market Cap: ~$100M

Technology Overview

NeuroStar Advanced Therapy

NeuroStar is a comprehensive TMS system:

| Component | Description |
|-----------|-------------|
| Treatment Coil | Figure-8 coil for targeted stimulation |
| Treatment Chair | Ergonomic patient positioning |
| Control System | Integrated software and hardware |
| Navigation | SmartCoil technology for targeting |
| Reporting | Treatment tracking and analytics |

Technical Specifications

• Magnetic field: 1.5-2.0 Tesla
• Frequency: 10 Hz standard protocol
• Pulses per session: 3,000 pulses
• Session duration: approximately 37 minutes
• Treatment course: 6 weeks (5 sessions per week)

FDA Clearances

| Indication | Clearance Year |
|------------|-----------------|
| Major Depressive Disorder | 2008 |
| Chronic pain | 2018 |
| OCD | 2022 |
| Adolescent MDD | 2024 |

Clinical Evidence

Overview

Neuronetics, Inc. (NASDAQ: STIM) is a medical device company developing and commercializing non-invasive neuromodulation therapies for the treatment of psychiatric and neurological disorders. Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics is the pioneer in Repetitive Transcranial Magnetic Stimulation (rTMS) technology for major depressive disorder (MDD)[@neuronetics2024].

The company flagship product, the NeuroStar Advanced Therapy system, is an FDA-cleared TMS device used by psychiatrists and neurologists to treat patients with major depressive disorder who have not responded to antidepressant medications[@us2008].

Funding

• IPO: 2020 (NASDAQ: STIM)
• Market Cap: ~$100M

Technology Overview

NeuroStar Advanced Therapy

NeuroStar is a comprehensive TMS system:

| Component | Description |
|-----------|-------------|
| Treatment Coil | Figure-8 coil for targeted stimulation |
| Treatment Chair | Ergonomic patient positioning |
| Control System | Integrated software and hardware |
| Navigation | SmartCoil technology for targeting |
| Reporting | Treatment tracking and analytics |

Technical Specifications

• Magnetic field: 1.5-2.0 Tesla
• Frequency: 10 Hz standard protocol
• Pulses per session: 3,000 pulses
• Session duration: approximately 37 minutes
• Treatment course: 6 weeks (5 sessions per week)

FDA Clearances

| Indication | Clearance Year |
|------------|-----------------|
| Major Depressive Disorder | 2008 |
| Chronic pain | 2018 |
| OCD | 2022 |
| Adolescent MDD | 2024 |

Clinical Evidence

depression-treatment" style="color:#e0e0e0;margin:1.2rem 0 0.5rem;font-size:1rem;font-weight:600;border-bottom:1px solid rgba(255,255,255,0.08);padding-bottom:0.3rem">Depression Treatment

NeuroStar has extensive clinical trial data:

| Study | Patients | Results |
|-------|----------|---------|
| SMART | 307 MDD patients | 58% remission rate |
| THREE | 229 treatment-resistant | Significant improvement |
| FORWARD | 409 patients | Durable response at 12 months |

Mechanism of Action

NeuroStar delivers magnetic pulses to the left prefrontal [cortex](/brain-regions/cortex):

• Target: Left dorsolateral prefrontal cortex (DLPFC)
• Neurotransmitter effects: Increased dopamine and serotonin
• Network effects: Normalizes frontal lobe hyperconnectivity
• Plasticity: Promotes neural circuit reorganization

Clinical Applications

Primary Indication

Major Depressive Disorder (MDD)

• Treatment-resistant depression
• Patients who failed one or more antidepressant
• Non-psychotic depression

Off-Label Uses

| Condition | Evidence Level |
|-----------|---------------|
| Bipolar depression | Emerging |
| PTSD | Growing |
| Chronic pain | Preliminary |
| Parkinson depression | Preliminary |

Market Position

TMS Competitive Landscape

| Company | Product | Technology | Market |
|---------|---------|------------|--------|
| Neuronetics | NeuroStar | rTMS 10Hz | Leader |
| Magstim | Rapid2 | rTMS | Significant |
| Brainsway | Deep TMS | Deep TMS | Growing |
| Nexstim | eSmart | Navigated TMS | Niche |

Key Differentiators

| Feature | NeuroStar Advantage |
|---------|-------------------|
| FDA history | First cleared TMS device |
| Clinical data | Extensive RCT evidence |
| Treatment network | Over 1,000 treatment centers |
| Reimbursement | Established CPT codes |

Business Model

Revenue Streams

• System sales: NeuroStar device
• Treatment payments: Per-session revenue
• Service contracts: Annual service agreements
• Supplies: Treatment coils and consumables

Reimbursement

• Medicare: Covered in most regions
• Commercial insurance: 80%+ coverage
• Veterans Affairs: Covered
• Self-pay: Available

Company Information

Financials

• Ticker: NASDAQ: STIM
• Market cap: approximately 50 million (2024)
• 2023 Revenue: approximately 0 million
• Employees: approximately 250

Leadership

• CEO: Steven M. Wieble
• CFO: Mark S. Williams
• CMO: Dr. Aaron M. Boogaard

Headquarters

Malvern, Pennsylvania, USA

Cross-References

• Transcranial Magnetic Stimulation
• Depression in Neurological Disease
• Neuromodulation
• Non-Invasive Brain Stimulation

See Also

• [Major Depressive Disorder](/diseases/major-depressive-disorder)
• [Parkinson Disease](/diseases/parkinsons-disease)
• [Neurological Disorders](/diseases/neurological-disorders)